Tweets
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush @RheumNow ( View Tweet )
6 days 21 hours ago
The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as
Dr. John Cush @RheumNow ( View Tweet )
6 days 22 hours ago
Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/jtHgVABFiA
Dr. John Cush @RheumNow ( View Tweet )
6 days 23 hours ago
Case-control study of 349 autoimmune (ARD) pts (SLE, RA, SSc) & serum assays for anti-neutrophil extracellular trap (aNET)Abs. aNET in 37% SLE assoc w/ APS (OR 3.4) & arterial thrombosis (OR 5.5). aNET in 40% RA assoc w/ ACPA+ (p=0.049) https://t.co/QwvmLAVmg7 https://t.co/VJ7JV5fcZE
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
Best JAKi? Italian Observational BIRRA Cohort study of 170 #PsA pts Rx w/ UPA or TOFA found no significance in 6 mos (86 vs 78%) or 12 mos (68 v 60%) retention. Persistence lower in pts Concomitant or later csDMARDs. https://t.co/vtSrO9orh4
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
"Courage is resistance to fear, mastery of fear, not absence of fear."
- Mark Twain https://t.co/xyJqiV7biI
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
Let me give you an example of where there is no gov intervention, and the impact on brand drug pricing.
When a brand manufacturer sells a drug to one of the big 3 drug distributors that control more than 90 pct of their market, those multi hundred billion dollar distributors
Mark Cuban @mcuban ( View Tweet )
1 week ago
A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD
Rheumatology update @aabdogafar ( View Tweet )
1 week ago
True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF
Dr. John Cush @RheumNow ( View Tweet )
1 week ago
